Cytosin-Arabinosid

ESCC

RenJi HospitalPhase 2Active

CCC

53/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 89/ 100

Competitive context

7 Active assets in the ESCC cohort.

Asset / Sponsor	Phase	Rating
Serplulimab RenJi Hospital	Phase 2	CCC
Daunorubicin RenJi Hospital	Phase 2	CCC
Surufatinib RenJi Hospital	Phase 2	CCC
Jab-8263 Jacobio Pharmaceuticals Co., Ltd.	Phase 1/2	CC
asp0739 Astellas Pharma Global Development, Inc.	Phase 1/2	CC
Nrm-823 Normunity AccelCo, Inc.	Phase 1	CC
alx2004 ALX Oncology Inc.	Phase 1	CC

Same molecule, other indications

Cytosin-Arabinosid is also rated in:

acute promyelocytic leukemiaDormant

A

Indicative ·

82 / 100

adult acute lymphoblastic leukemiaDormant

BBB

Indicative ·

79 / 100

B-cell childhood acute lymphoblastic leukemiaDormant

BBB

Indicative ·

78 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.